Kazia Therapeutics to Present at LD Micro Main Event
SYDNEY, Oct. 6, 2021 /PRNewswire/ — Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that CEO, Dr James Garner, will be presenting at the LD Micro Main Event, to be held virtually and in person from 12-14 October 2021.
Since 2008, the LD Micro Main Event has established itself as one of the leading conferences for small-cap companies across a wide range of sectors. This year’s event will see approximately 120 participating companies, with presentations over three days. The conference will be conducted in a hybrid format, with a virtual component and an in-person component at the Luxe Sunset Bel Air hotel in Los Angeles, CA.
Dr Garner’s presentation will review some of the important developments in Kazia over calendar 2021, which include three cross-border licensing deals and commencement of an international pivotal study for the company’s lead asset, and will also indicate some of the anticipated developments for the company during the fourth quarter and into calendar 2022.The Kazia presentation will be available at 10am, ET, on Tuesday, October 12, 2021 (1:00am, AEDT, on Wednesday, 13 October 2021). Registration to the conference is complimentary and can be accessed via the conference website at:https://me21.mysequire.com/
Expand